| (Values in U.S. Thousands) | May, 2025 | Feb, 2025 | Nov, 2024 | May, 2024 | Feb, 2024 |
| Sales | 1,803 | 1,512 | 2,014 | -9,803 | 4,349 |
| Sales Growth | +19.21% | -24.90% | +120.54% | -325.42% | -13.56% |
| Net Income | -711 | -9,165 | -1,202 | -3,527 | -5,755 |
| Net Income Growth | +92.24% | -662.38% | +65.92% | +38.72% | +3.35% |
Numinus Wellness Inc (NUMI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.
Fiscal Year End Date: 08/31